GEn1E Lifesciences Inc. (“Genie”) is a biotechnology company that turbocharges cures for rare and neglected diseases. By focusing on treatments for rare diseases, we optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.
GEn1E has a pipeline of 2 preclinical stage products. The first is a P38 kinase inhibitor for the treatment of various inflammatory and aging diseases. The second is an endogenous non-antibiotic anti-bacterial agent for the treatment of Pseudomonas infections.
Who WE ARE
GEn1E’s team includes like-minded professionals with deep experience in Business Development and Strategy, Chemistry, Clinical, Formulations, CMC, Toxicology, Regulatory, Bio-Statistics, PK/ADME, Bioanalytical, Health Economics, IP Law, and Communications.